ORDER A TEST Log In Contact Us
Hero Background

LIFE SCIENCES

The operating system for precision medicine 2.0

One comprehensive platform that offers biopharma speed, scale, and integrated solutions for all lifecycle stages.

CONTACT US

Click the boxes below to learn more about how Tempus is advancing precision medicine throughout the drug lifecycle

  • Research

    Help de-risk and accelerate the path to clinic

    Learn more
  • Clinical Development

    Boost confidence at each developmental milestone

    Learn more
  • Commercialization

    Understand and take action on real-world experience

    Learn more
Research

Help de-risk and accelerate the path to clinic

Learn more
Disease Biology

Uncover deeper insights regarding tumor heterogeneity, resistance mechanisms, and interaction within the tumor microenvironment to support targeted development strategies. Integrate tumor organoid models, multimodal data, multi-omic profiling, and AI-driven analytics to map oncogenic pathways, characterize immune evasion strategies, and identify tumor vulnerabilities.

Learn more
AI and Drug Screening
Drug screening with advanced imaging capabilities

Learn how noninvasive imaging techniques allow for continuous study of organoids.
Characterizing Unmet Needs

Leverage real-world data and epidemiological modeling to quantify disease burden and survival disparities, helping uncover potential resistance-associated biomarkers and high-impact subpopulations. Evaluate treatment gaps through real-world evidence to guide development prioritization.

Learn more
Research Characterizing Unmet Needs
Bristol Myers Squibb Collaboration

Identifying and validating targets with multimodal data, computation, and patient-derived models.
Clinical Trial Design
Real-world Outcomes & Value
Target Validation & Lead Optimization

Explore a target’s involvement in cancer progression and therapeutic actionability. Assess target expression, function, and druggability using tumor organoid models to evaluate its biological relevance. Leverage real-world toxicity, resistance, and treatment-response data to further validate targets and refine drug candidates.

Learn more
QA A deep dive into the science and significance of Tempus Immune Profile Score IPS
Validating Immune Profile Score (IPS)

Dr. Michelle Ting-Lin, discusses the science behind a novel biomarker and ICI prognosticator.
Biomarker Strategy

Validate and refine biomarkers using tumor organoids and multimodal data to assess predictive, prognostic, or pharmacodynamic utility. Leverage insights generated to optimize patient stratification and response monitoring throughout clinical development.

Learn more
QA Advancing immunotherapy biomarker identification with Immune Profile Score IPS
Advancing immunotherapy biomarker identification

Jason Blue-Smith discusses IO biomarker challenges and how Tempus IPS provides solutions.
Clinical Trial Execution
Care Gaps Closure
Novel Target Identification

Investigate possible novel target candidates while considering oncogenic dependencies via high-throughput functional screening. Refine candidate selection using computational modeling and AI-powered omics solutions to predict druggability, pathway redundancy, and tumor specificity. Investigate therapeutic relevance of emerging targets through validation studies using tumor organoid models, enabling a data-based prioritization of first-in-class or best-in-class therapeutic approaches.

Learn more
QA Harnessing AI with multimodal data to transform drug development
Harnessing AI with multimodal data

Dr. Kate Sasser, PhD, discusses layering ML and AI on RWD to drive insights in drug discovery.
Indication Selection

Identify tumor types and patient populations that may benefit from a therapeutic candidate by integrating disease biology, biomarker insights, and clinical unmet needs. Refine clinical development strategies to support efficient resource allocation and increase the probability of technical success.

Learn more
Clin Dev Clinical Trial Design and Indication Selection
Revolutionize drug screening

How Tempus AI’s imaging enables continuous organoid study across assays, preserving testing viability.
IUO Validation & CDx Development
Clinical Development

Boost confidence at each developmental milestone

Learn more
Disease Biology
Characterizing Unmet Needs
Clinical Trial Design

Analyze contemporaneous, real-world, multimodal data to characterize tumor heterogeneity, enabling the integration of those insights into trial I/E criteria. Refine trial endpoints to improve the probability of technical success and effectively evaluate drug efficacy across diverse patient populations. Assess the impact of different methods for generating standard-of-care performance data as comparators.

Learn more
Strategically simulate and contextualize data

Mirati leverages Tempus RWD to revise its KRAS strategy and refine patient selection.
Real-world Outcomes & Value
Target Validation & Lead Optimization
Biomarker Strategy

Leverage multimodal data to refine biomarker-driven patient selection criteria and optimize trial design for regulatory review. Integrate biomarker assays into clinical trial workflows to help maximize the probability of technical success and accelerate the path toward CDx submission.

Learn more
Case Study AstraZeneca reduces time to launch
Reduce time to launch with multimodal data

Learn how AstraZeneca simplified its approach to TROPION-Lung01 and drove down time to launch.
Clinical Trial Execution

Optimize site selection and leverage real-world data for feasibility assessments. Tap into an extensive provider network equipped with algorithmic patient-matching workflows to accelerate enrollment. Execute clinical trials efficiently by leveraging data-driven insights.

Learn more
Case Study Sermonix TIME Program
Activate trial sites faster

Sermonix was able to accelerate timelines for first patient in and enrollment by working with Tempus.
Care Gaps Closure
Novel Target Identification
Indication Selection

Explore multimodal datasets and leverage AI-driven analytics to investigate indications with high unmet need. Implement a strategic approach to indication selection informed by tumor heterogeneity across subpopulations and standard of care landscape dynamics to help optimize resource allocation, accelerate time to market, and expand label opportunities.

Learn more
Clin Dev Clinical Trial Design and Indication Selection
PAVO: Assessing the safety and efficacy of niraparib (PARPi)

Accelerating clinical trial start-up and execution with an end-to-end approach.
IUO Validation & CDx Development

Delve into real-world data to understand biomarker prevalence and utilize comprehensive genomic profiling to support IDE studies. Establish robust analytical and clinical validation studies, aligning CDx development strategies with therapeutic trial timelines. All on a broadly distributed platform.

Learn more
Case Study A2 Biotherapeutics with CDx
Enhance clinical development with Tempus’ CDx platform

A2 Biotherapeutics uses HLA-LOH as a biomarker to progress breakthrough cell therapy.
Commercialization

Understand and take action on real-world experience

Learn more
Disease Biology
Characterizing Unmet Needs
Clinical Trial Design
Real-world Outcomes & Value

Synthesize a comprehensive view of each patient and population. Evaluate therapeutic safety, efficacy, and long-term benefits with integrated clinical, molecular, claims, and outcomes data. Generate RWE to assist regulatory decision-making, inform HEOR, and facilitate reimbursement negotiations.

Learn more
Case Study NSCLC
Get more insights faster with multimodal data

Tempus collaborates with Pfizer to further profile HER2 expression across various cancers.
Target Validation & Lead Optimization
Biomarker Strategy
Clinical Trial Execution
Care Gaps Closure

Leverage an AI-enabled care pathway platform that empowers providers to deliver the next step in a patient’s care journey. Integrate RWE into clinical strategies to help bridge gaps in early diagnosis, treatment adherence, and long-term patient outcomes.

Learn more
Case Study Pfizer HER2 Expression
Closing biomarker testing gaps for early-stage NSCLC patients

TriHealth Cancer and Blood Institute surfaces and closes care gaps with Next.
Novel Target Identification
Indication Selection
IUO Validation & CDx Development
  • 8M+

    de-identified research records

  • 600+

    direct data connections across 3K+ health institutions

  • 10

    NGS tests to support clinical trial and research sequencing

  • 6.5K+

    oncologists are connected to Tempus

  • 60+

    care gap modules launched

image description

Explore our customer success stories to see why Tempus is a trusted partner for 95% of the top 20 pharma companies* and more than 200 biopharma companies.

AstraZeneca

Learn how AstraZeneca integrated Tempus data and tools across their Oncology R&D governance process.

Read Case study

Mirati Therapeutics

Make quicker decisions by simulating and contextualizing data with Tempus

Read Case study

Recursion

Advancing biomarker-driven therapeutic development with a data-first approach

Read press release

Pfizer

Furthering profile HER2 expression across various cancers with multimodal data

Read Case study

Sermonix

Patient recruitment

Read article

Bristol Myers Squibb

Identify new targets and validate them faster and with higher confidence using multimodal datasets, computational approaches, and patient-derived disease models in specific cancer disease areas

Read Press release

BioNTech

A collaboration to generate novel insights into the biological mechanisms supporting the discovery of new cancer therapeuitcs

Read Press release

GSK

Leveraging diagnostics and data to drive next-generation drug development

Watch webinar

Eisai

The evolution of RWE and HEOR

Read article

Stemline Therapeutics, Inc.

Closing ESR1 testing gaps with an AI-enabled care pathway intelligence platform

Read Press release

MD Anderson Cancer Center

ADCs in focus: The next generation of precision medicine in oncology

Watch webinar

JW Pharmaceutical

Applying real-world data and biological modeling to enhance early research and development

Read press release

Takeda

Leveraging multimodal real-world datasets and biological model systems in oncology R&D

Read Press release

Remix Therapeutics

Interrogating specific cohorts with real-world datasets

Read Press release

United Therapeutics

Develop and investigate AI-based medical device software to detect patients at risk of having undiagnosed pulmonary hypertension (PH)

Read press release

IFLI

Derive AI-driven insights to accelerate the development of follicular lymphoma treatments in an effort to improve patient outcomes

Read Press release

TScan

Partner to develop assays

Read press release

Aadi Bioscience

Accelerate trial enrollment

Read case study

AstraZeneca

Increasing Probability of Technical Success (PTS)

Read blog

Gilead

RWD and decision making

Read article

AstraZeneca

Multimodal data for Probability of Technical Success (PTS)

Watch webinar

Kronos Bio

RWE for drug development

Read article

AstraZeneca

Clinical trials for novel therapies

Read press release

Actuate Therapeutics

Use liquid biopsy and RUO DNA Methylation to discover and validate

Read press release

Gilead

Biomarker innovation

Watch webinar

Sermonix

Accelerating tiral enrollment in ELAINE II

Read case study

A2 Bio

NGS to power R&D

Read article

AstraZeneca and Pfizer

Data-driven CDx development

Read article

TScan

RWD and immuno-oncology

Read article

GSK

Using data and AI/ML to achieve precision medicine

Watch article

Janssen

Using RWD

Read article

GSK

Intersection of genomics and machine learning

Read press release

Kartos Therapeutics

Progressing the goal of innovative therapies

Read press release

Eli Lilly

Increasing accessibility to testing

Read press release

Geisinger

AI and ECG

Read blog

Genmab

Multimodal RWD

Read article

Janssen

Leveraging AI/ML for RWD

Read press release

AstraZeneca

Strategic collaboration

Read press release

Kronos Bio

Collaboration around data and organoids

Read press release

Bristol Myers Squibb

Discover RNA based targets

Read press release

Genmab

Discover new targets

Read press release

Kronos

Advancing transcriptional cancer therapies with comprehensive life science solutions

Read Case study
Our Impact

Thanks to Tempus, we are able to identify patients that can be helped with our proprietary TMod™ platform. Without them, we wouldn’t be able to do this.

William Go, SVP, Head of Development at A2 Biotherapeutics (TMod™ is a trademark of A2 Biotherapeutics)

Our Impact

Tempus is a leader in the field of personalized medicine, and like Genmab, Tempus has a mission to improve the lives of cancer patients. We are looking forward to expanding our exciting partnership with them and to the possibility of discovering important new oncology targets and biomarkers.

Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab

Learn more about our partnership with Genmab
Our Impact

Bayer’s strong focus in precision medicine combined with Tempus’ unique testing offering has culminated in this collaboration to bring genomic testing to cancer patients.

Bhavesh Ashar, Senior Vice President, Head of U.S. Oncology at Bayer

Learn more about our partnership with Bayer
Our Impact

[Working with Tempus Data] gives you more confidence in the drug as you’re designing a study… it helped us understand what patients are going on 2nd line and benefitting from docetaxel vs. those patients who are not benefitting.

LEORA HORN, MD, Global Clinical Head for Lung Cancer & Lung Cancer Strategy. AstraZeneca

Learn more about our partnership with AstraZeneca

Explore by Solution

  1. Sequencing

    Use our genomic platform to prospectively sequence through clinical trials and retrospectively support research priorities.
  2. Data Collaborations

    Leverage real-world datasets of matched molecular and clinical data with digital whole slide pathology images to uncover new insights across the research and development spectrum.
  3. Biological Modeling

    Leverage our vast tumor organoid repository to accelerate drug discovery.
  4. Companion Diagnostics

    Integrate CDx claims into Tempus assays through a validated and established sequencing platform to pursue companion diagnostic biomarkers.
  5. Omics Solutions

    Discover unique molecular targets, track methylation patterns, and build multimodal datasets with our robust suite of high throughput multi-omic solutions.

  6. Clinical Research Organization Services

    Bring discoveries from the lab to market through our full-service CRO.
  7. Clinical Trial Enrollment

    Utilize NGS and EMR integrations to identify patients that match your study's eligibility criteria, including targetable biomarkers from DNA and RNA.
  8. Tempus Studies

    Leverage our end to end solutions to design and execute Tempus-sponsored clinical trials for therapeutics, devices, and diagnostics from study concept to registrational filing.
  9. Care Gap Solutions

    Timely AI-enabled notifications to accelerate adoption of precision care pathways and avoid gaps in care.
  10. AI-enabled Algorithms

    Harness multimodal data, AI/machine learning (ML), and bioinformatics to help develop, validate, and deploy molecular algorithms.

Featured Resources

View all RESOURCES
  • UPCOMING WEBINAR:

    Enhancing psychiatric care with pharmacogenomics (PGx)

    Tune in as clinicians discuss PGx, and its application in psychiatric medication management. Our expert speakers will guide you through patient case studies and real-world PGx reports, and highlight the role of pharmacogenomics to inform personalized treatment decisions in mental health.

    Watch replay
  • UPCOMING WEBINAR:

    Q&A: Advancing immunotherapy biomarker identification with Immune Profile Score (IPS)

    Jason Blue-Smith, VP & GM of Algos at Tempus, discusses the challenges in immunotherapy biomarker identification and how Tempus’ Immune Profile Score (IPS) offers solutions to these problems.

    Read more
  • UPCOMING WEBINAR:

    Integrating Omics in R&D: A new era of biomedical research

    Industry experts discuss the integration of diverse omics data, from next-generation sequencing (NGS) to proteomics, and explore its transformative impact on the research landscape.

    Watch replay
  • UPCOMING WEBINAR:

    Tempus receives U.S. FDA 510(k) clearance for TEmpus ECG-AF, an AI-based algorithm that identifies patients at increased risk of AFib

    Tempus AI, Inc. (NASDAQ: TEM), a leader in AI and precision medicine, announced it has received 510(k) clearance from the FDA for its Tempus ECG-AF device. This AI-based algorithm helps identify patients who may be at increased risk of atrial fibrillation/flutter (AF), marking the first FDA clearance for an AF indication in the "cardiovascular machine learning-based notification software" category.

    Watch replay
  • UPCOMING WEBINAR:

    Embracing AI in oncology: A fireside chat with industry leaders at AACR 2024

    Industry leaders highlight the importance of multimodal data, AI-driven diagnostics, and the necessity of innovative approaches to meet the challenges of oncology treatment.

    Watch now
  • UPCOMING WEBINAR:

    ADCs in focus: The next generation of precision medicine in oncology

    Watch this engaging discussion as thought leaders explore the evolving landscape of antibody-drug conjugates (ADCs) in cancer therapeutics, including resistance mutations in first-gen ADCs, combination strategies with immune checkpoint inhibitors (ICIs), and next-gen targets and technologies. Tempus is dedicated to enhancing ADC development by offering comprehensive genomic profiling, multimodal de-identified real-world data (RWD), and AI-enabled solutions, informing target discovery and clinical trial optimization for more personalized therapies.

    Watch replay
  • UPCOMING WEBINAR:

    Advancing transcriptional cancer therapies with Tempus’ comprehensive life science solutions

    Kronos Bio, a trailblazer in the biopharmaceutical industry, is dedicated to the discovery and development of novel therapies that target transcriptional regulation in cancer. Kronos turned to Tempus’ comprehensive suite of solutions to propel its principal asset from discovery to clinical trials.

    Read more
  • UPCOMING WEBINAR:

    Q&A: Using AI to identify and close gaps in care for cancer patients

    Navigating the dynamic landscape of FDA approvals and complex clinical guidelines is an ongoing challenge for healthcare providers.

    Watch replay
  • UPCOMING WEBINAR:

    Accelerating ADC development with Tempus AI

    Empowering precision and efficiency in ADC therapeutics with advanced data analytics.

    Read more

*Based on publicly available 2022 segment revenue

Trusted by hundreds of biopharma to power drug development

Discover AI-enabled precision medicine

Contact us to learn more.